Will Merck Post More Than $470 Million In Pembrolizumab Sales For All Of Q4 2016, Tomorrow?

Well. . . we should know by early tomorrow morning.

That $470 million figure is what The Street is expecting. I personally wouldn’t be surprised if Kenilworth beats that, breaking $500 million for the quarter — since it has had a run of good results, from trials. And those should have translated into at least some off-label (or still technically experimental) deployments. We shall see. A bit — but do go read it all:

. . . .The FDA in October approved Keytruda for the first-line treatment of patients with metastatic NSCLC whose tumors have high expression of PD-L1 with no EGFR or ALK genomic tumor aberrations. . . .

I’ll endeavor to live blog anything particularly note-worthy — but in general I expect an in-line quarter, with some 3 per cent sales headwind, due to currencies. Now you know — g’night, all.



There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: